Placeholder Banner

BIO Sends Letter to President Trump on U.S.-China Trade & Biotech

December 18, 2018

BIO sent a letter to President Trump following his meeting with President Xi of the People’s Republic of China, welcoming the news the United States and China have begun talks to address important issues including forced technology transfer, intellectual property protection, and agriculture. BIO reminded President Trump of the need to resolve systemic barriers to China’s timely approvals of new agricultural biotechnology products, the approval of all pending products that have languished for years, and intellectual property rights protection of U.S.  biomedical products are paramount to continued U.S. innovation, competitiveness, and export growth.

Download Full Comments Below
BIO Letter To POTUS From Jim Greenwood 12-19-2018
BIO Letter to POTUS on U.S./China Trade
Discover More
On November 9, BIO submitted comments on the FDA Draft Guidance, Drug-Drug Interaction Assessment for Therapeutic Proteins. In the comments, BIO thanks the FDA for the opportunity to submit comments but requests that the Guidance include a…
On August 6, BIO submitted comments on the NMPA Draft Technical Guideline on Clinical Trials of Cellular Immunotherapy Products. In the comments, BIO thanks NMPA for the opportunity to submit comments but argues for a more robust commenting period…
October 30, 2020 Re: Docket No. FDA–2020-D-1564: FDA Draft Guidance, Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation. Dear Sir/Madam: The Biotechnology…